Nevertheless, tirzepatide and semaglutide both led to a decrease in the respiratory exchange ratio [1] during the first two weeks of treatment, suggesting an increase in fat oxidation and a ...

Experts suggest that tirzepatide’s dual mechanism of action, targeting two metabolic receptors, may explain its superior weight-loss results compared to semaglutide’s single-receptor approach.

At 52 weeks, the tirzepatide group bested the placebo group in a 6-minute walk test by 18.3 meters and had lost an average of 13.9% body weight vs 2.2%, for a difference of 11.6%.

Furthermore, patients on tirzepatide saw an average body weight reduction of 15.7% against 2.2% in the placebo group. A reduced high-sensitivity C-reactive protein (hsCRP) level of 43.4% is also ...

There is a low but increased risk of optic nerve disorders in patients with type 2 diabetes prescribed semaglutide or ...

Novo Nordisk’s GLP-1 drug Wegovy expanded its label to include the metabolic disorder known as MASH. Analysts say there’s ...

After 52 weeks on tirzepatide, those who lost more weight had bigger gains in their 6-minute walk distance and changes in the KCCQ-CSS (P < .0001 for both). The same benefits were seen in those ...

With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug ...

FDA confirms shortage of weight loss drug tirzepatide is over, gives compounders a grace period The action could set a precedent for how the agency handles Novo Nordisk’s semaglutide ...

Compounded tirzepatide is not approved by the FDA. This means the FDA does not regulate the safety, quality, or effectiveness of the drug. Instead, each state regulates its compounding pharmacies.

The Food and Drug Administration said Thursday it’s standing by its earlier decision that the shortage of tirzepatide — the active ingredient in Eli Lilly’s diabetes and weight loss drugs ...